Intelligent Bio Solutions Inc. (NASDAQ:INBS – Get Free Report) was the target of a large drop in short interest in February. As of February 13th, there was short interest totaling 33,513 shares, a drop of 74.6% from the January 29th total of 131,837 shares. Based on an average trading volume of 90,292 shares, the short-interest ratio is currently 0.4 days. Approximately 2.1% of the company’s stock are sold short. Approximately 2.1% of the company’s stock are sold short. Based on an average trading volume of 90,292 shares, the short-interest ratio is currently 0.4 days.
Wall Street Analyst Weigh In
INBS has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intelligent Bio Solutions in a report on Thursday, January 22nd. Wall Street Zen raised shares of Intelligent Bio Solutions to a “sell” rating in a research note on Saturday, January 31st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.
Read Our Latest Stock Report on Intelligent Bio Solutions
Institutional Inflows and Outflows
Intelligent Bio Solutions Price Performance
INBS stock traded up $0.59 during trading on Friday, hitting $4.50. 285,959 shares of the stock traded hands, compared to its average volume of 129,496. Intelligent Bio Solutions has a 1 year low of $3.70 and a 1 year high of $25.00. The stock has a market cap of $7.20 million, a price-to-earnings ratio of -0.30 and a beta of 4.48. The firm’s 50 day moving average is $8.24 and its two-hundred day moving average is $10.00.
Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported ($2.82) earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($3.22). The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $5.50 million. Intelligent Bio Solutions had a negative net margin of 315.33% and a negative return on equity of 200.68%. As a group, analysts anticipate that Intelligent Bio Solutions will post -1.25 EPS for the current fiscal year.
Intelligent Bio Solutions Company Profile
Intelligent Bio Solutions, Inc, through its wholly owned subsidiary, is focused on the design, development and marketing of rapid, real-time detection and identification systems for foodborne and environmental pathogens. The company’s flagship product, the RAPID-B System, integrates patented biosensor and fluorescence technologies to detect viable microorganisms in a fraction of the time required by traditional culture-based testing methods. This approach enables food processors, beverage producers, environmental testing laboratories and homeland security agencies to identify contaminants such as Escherichia coli O157:H7, Salmonella spp.
Featured Articles
- Five stocks we like better than Intelligent Bio Solutions
- 3 Signs You May Want to Switch Financial Advisors
- Buy This Stock Now
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- Your name isn’t on our protected list yet
- Elon Musk already made me a “wealthy man”
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
